Phase 3 trial with an adalimumab reference group in children with juvenile psoriatic or enthesitis-related arthritis: at week 16, 90% (54/60) of biologic-naive and 86% (18/21) of biologic-experienced ixekizumab patients had a JIA-ACR30 response; no severe adverse events.
RCTn = 101
Ramanan et al. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab